• CanSino Biologics received NMPA acceptance for a supplemental application to expand Menhycia’s indicated age range to 3 months–17 years.
• Menhycia, China’s first MCV4 meningococcal conjugate vaccine, is currently approved for children aged 3 months–6 years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260719-12248943), on July 19, 2026, and is solely responsible for the information contained therein.